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http://dx.doi.org/10.1016/j.cell.2015.10.015Flibanserin acts at cortical, limbic, hypothalamic, and 
brainstem nuclei to inhibit serotonin release by binding to 
5-HT1A autoreceptors and block postsynaptic action of 
serotonin at 5-HT2A receptors. This gradually disinhibits 
the turnover of other monoamines like dopamine and 
noradrenaline that are critical for sexual desire.
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Bremelanotide | melanocortin receptor agonist
Lybridos | testosterone-coated sildenafil LybNAME
Flibanserin (Addyi)
APPROVED FOR 
Treatment of hypoactive sexual desire disorder (HSDD) in women
TYPE
Small molecule: centrally active piperazine/benzimidazol derivative
MOLECULAR TARGETS
Full agonist at 5-HT1A receptors, antagonist at 5-HT2A receptors. 
Reduces forskolin-stimulated cAMP and eliminates 5-HT-stimulated 
phosphatidyl-inositol turnover in cortex.
CELLULAR TARGETS
Reduction of serotonin-induced descending inhibition in medial 
prefrontal cortex, limbic regions, hypothalamus, and brainstem.
EFFECTS ON TARGETS
Disinhibition of dopamine (DA) and noradrenaline (NE) turnover within 
cortical, limbic, and hypothalamic regions associated with the 
stimulation of sexual desire.
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Boehringer Ingelheim ﬁles FDA application 
to treat HSDD with ﬂibanserin 
2010
Citing weak effects on daily diary 
desire reports, FDA committee 
rejects ﬂibanserin
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FDA panel accepts that 
HSDD is an unmet 
medical need
2015
After examination of 
new data, ﬂibanserin 
approved by the FDA
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Lorexys | combination of trazodone and bupropion
ridos | testosterone-coated buspirone
